The new Emerging Markets report entitled Type 2 Diabetes in Brazil also finds that diagnosis rates of type 2 diabetes in Brazil are far lower than diagnosis rates in major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan). One of the key reasons for this is low disease awareness and poor understanding of type 2 diabetes symptoms among patients, which prevents them from seeking treatment.

"This challenge in diagnosis rates of type 2 diabetes in Brazil is a great opportunity for Western drug companies. Western drug companies should reach out and work with the Brazilian government and policy makers to launch programs that raise disease awareness and promote patient education among the general population in Brazil. These programs can also provide patients with more information on the latest novel therapeutic agents and lead to increased drug sales by multinational drug companies," added Ms. Wu.

The new report contains primary research of physicians and epidemiology study in key pharmaceutical markets of Brazil -- Rio de Janeiro, Sao Paulo, Brasilia and Belo Horizonte.

SOURCE Decision Resources